Last week the Agency for Healthcare Research and Quality (AHRQ) informed dozens of investigators that they would not receive future installments for their ongoing grants. The communications were issued as letters of “non-award,” which told recipients that AHRQ was adjusting its discretionary health services research award portfolio and would not continue funding for certain projects. STAT reviewed at least one such letter that framed the decision as an agency-level prioritization of resources rather than a comment on individual grant performance.
The letters left many recipients abruptly without scheduled support for ongoing research activities. According to the reporting, investigators had in many cases already been experiencing months of uncertainty while waiting for renewed funding or seeking explanations from agency staff about interruptions in disbursements.
AcademyHealth, a membership organization representing health services researchers, confirmed that at least 78 grants were affected. Those awards had a combined remaining balance estimated at $109.2 million, and AcademyHealth reported that roughly $200 million in total grant value was implicated by the agency’s adjustments. The source did not provide a breakdown of the affected grants by institution, project topic, or specific dollar amounts per award beyond the aggregate estimate.
The non-award letters that STAT reviewed stated that AHRQ is adjusting its discretionary health services research award portfolio “in order to better prioritize agency resources towards the above-mentioned priorities to best serve the interests of the Federal Government.” The agency listed prioritized topics that include patient safety, antibiotic resistance, artificial intelligence (AI), long Covid, nutrition, and research to improve understanding of autism. The source’s reporting indicates that the decision was presented as a strategic reprioritization at the agency level.
Details on how priorities were weighted, how decisions were made for specific grants, or whether any affected projects might be reconsidered for future funding were not reported in the source article.
Investigators who received the notices expressed frustration, according to the reporting, though the news itself was described as largely unsurprising by many researchers who had been awaiting funding decisions or had difficulty obtaining clear explanations from AHRQ staff. The funding interruptions amplified concerns about the stability of support for the broader field of health services research and about the capacity of affected teams to continue planned work without alternative resources.
AcademyHealth’s confirmation of the number and scale of affected grants underscores the institutional and sector-level impact of the agency’s decision, but the source did not quote individual researchers or institutional leaders about the immediate operational consequences for specific projects.
The reporting notes that the notices came with about two months remaining in the fiscal year. The article also reported that AHRQ had spent only a small portion of its appropriated funds during the year at the point described, contributing to the puzzling context for recipients of the non-award notices. The source did not provide detailed fiscal figures beyond the cited estimates of unspent grant balances or a comprehensive timeline of when individual grants would have received future installments absent the non-award determination.
The source did not report several potentially relevant details. It did not identify the specific institutions, principal investigators, or projects affected beyond the aggregate counts and dollar estimates supplied by AcademyHealth. It did not present AHRQ’s internal documentation or detailed criteria explaining why particular awards were discontinued, nor did it report whether affected investigators would receive transitional support or be eligible to reapply under the newly emphasized priorities.
Researchers remain uncertain about how the reprioritization will affect the health services research workforce and ongoing studies. The source documents the portfolio adjustment and the areas AHRQ plans to emphasize, but additional information on implementation, timelines for potential reallocation, or remedies for disrupted projects was not reported.
Summary
STAT’s reporting describes a sudden and consequential adjustment by AHRQ that led to the early termination of future grant installments for dozens of health services research awards, leaving an estimated $109.2 million in remaining funding across affected grants. The action was framed by the agency as a portfolio reprioritization toward topics such as patient safety, antibiotic resistance, AI, long Covid, nutrition, and autism research. The source documents the scale and stated rationale but does not report granular details about which projects or investigators were cut, the process used to select awards for termination, or next steps for affected researchers.